- Home
- EDSA vs APM Comparison
EDSA vs APM Comparison
Compare EDSA & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDSA
- APM
- Stock Information
- Founded
- EDSA 2015
- APM 2010
- Country
- EDSA Canada
- APM United Kingdom
- Employees
- EDSA N/A
- APM N/A
- Industry
- EDSA Biotechnology: Pharmaceutical Preparations
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- EDSA Health Care
- APM Health Care
- Exchange
- EDSA Nasdaq
- APM Nasdaq
- Market Cap
- EDSA 6.2M
- APM 6.7M
- IPO Year
- EDSA N/A
- APM 2018
- Fundamental
- Price
- EDSA $2.26
- APM $0.83
- Analyst Decision
- EDSA Strong Buy
- APM
- Analyst Count
- EDSA 1
- APM 0
- Target Price
- EDSA $21.00
- APM N/A
- AVG Volume (30 Days)
- EDSA 11.4K
- APM 134.0K
- Earning Date
- EDSA 05-09-2025
- APM 04-29-2025
- Dividend Yield
- EDSA N/A
- APM N/A
- EPS Growth
- EDSA N/A
- APM N/A
- EPS
- EDSA N/A
- APM 0.00
- Revenue
- EDSA N/A
- APM N/A
- Revenue This Year
- EDSA N/A
- APM $157,729.10
- Revenue Next Year
- EDSA N/A
- APM N/A
- P/E Ratio
- EDSA N/A
- APM $258.24
- Revenue Growth
- EDSA N/A
- APM N/A
- 52 Week Low
- EDSA $1.55
- APM $0.46
- 52 Week High
- EDSA $5.59
- APM $7.88
- Technical
- Relative Strength Index (RSI)
- EDSA 46.91
- APM 47.05
- Support Level
- EDSA $2.11
- APM $0.70
- Resistance Level
- EDSA $2.34
- APM $1.34
- Average True Range (ATR)
- EDSA 0.13
- APM 0.11
- MACD
- EDSA -0.01
- APM 0.02
- Stochastic Oscillator
- EDSA 40.45
- APM 21.74
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.